Health Condition 1: D509- Iron deficiency anemia, unspecified
Conditions
Interventions
Intervention1: NIL: NIL
Control Intervention1: NIL: NIL
Sponsors
Indchemie Health Specialities Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18 years and above. 2. Diagnosed with Iron Deficiency Anaemia. 3. Prescribed either Ferrous Fumarate in combination with Protein Hydrolysate that is Cheri Capsule or Ferrous Ascorbate as part of routine clinical practice. 4. Willing and able to provide written informed consent. 5. Willing to comply with study assessments and follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity to study medications. 2. Patients with anaemia due to causes other than iron deficiency. 3. Patients receiving parenteral iron therapy. 4. Patients participating in another interventional clinical study. 5. Patients who, in the opinion of the investigator, are unsuitable for participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean change in haemoglobin Hb from baseline to Week 12 between patients receiving Ferrous Fumarate in combination with Protein Hydrolysate that is Cheri Capsule and those receiving Ferrous Ascorbate.Timepoint: baseline and week 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in serum ferritin serum iron transferrin saturation that is TSAT and total iron binding capacity that is TIBC.Timepoint: Baseline and week 12;Change in Fatigue Severity Scale that is FSS score.Timepoint: baseline and week 12;Incidence and severity and relationship of adverse events.Timepoint: from baseline until week 12 | — |
Countries
India
Contacts
Public ContactDr Punit Srivastava
Mediception Science Pvt Ltd
Outcome results
None listed